Amicus Therapeutics Inc. (NASDAQ:FOLD) rose 4.7% during trading on Friday . The stock traded as high as $6.03 and last traded at $5.96, with a volume of 966,127 shares. The stock had previously closed at $5.69.

FOLD has been the subject of several research reports. Chardan Capital boosted their price objective on Amicus Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, April 12th. Goldman Sachs Group Inc. started coverage on Amicus Therapeutics in a research report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 price target for the company. Robert W. Baird started coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price target for the company. Leerink Swann restated an “outperform” rating and issued a $19.00 price target (up from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Finally, Bank of America Corp. started coverage on Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $12.88.

The firm’s market capitalization is $769.92 million. The firm has a 50-day moving average of $6.13 and a 200 day moving average of $7.01.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.01. Equities research analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.

In related news, General Counsel Ellen Rosenberg purchased 15,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, June 2nd. The stock was bought at an average cost of $7.67 per share, for a total transaction of $115,050.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Several large investors recently bought and sold shares of the stock. Nationwide Fund Advisors increased its stake in Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,754 shares during the last quarter. TD Asset Management Inc. increased its stake in Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares during the last quarter. Swiss National Bank increased its stake in Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares during the last quarter. California Public Employees Retirement System increased its stake in Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 11,600 shares during the last quarter. Finally, ProShare Advisors LLC increased its stake in Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.